43 recent developments neod001 for al amyloidosis in october 2015 , we announced plans to initiate pronto , a phase 2b registration-directed global , multi-center , randomized , double-blind , placebo-controlled clinical trial for neod001 in previously treated patients with al amyloidosis and with persistent cardiac dysfunction . the pronto trial is designed to enroll approximately 100 patients with a primary diagnosis of al amyloidosis and persistent cardiac dysfunction despite previous treatment with off-label , plasma cell directed therapy . patients will be randomized on a 1:1 basis to receive 24 mg/kg of neod001 or placebo via intravenous infusion every 28 days . the primary endpoint is cardiac best response as assessed by nt-probnp measured over 12 months . secondary endpoints include evaluations of short form 36 , six-minute walk test , and renal response as assessed by proteinuria . prothena designed the study with 80 % power to detect an absolute difference of 26.5 % in nt-probnp best response rate between the treatment and placebo groups with a two-sided alpha of 0.05. in october , we also announced the completion of enrollment for the expansion cohort of the phase 1/2 study of neod001 to treat patients with al amyloidosis and persistent organ dysfunction . based on strong interest from patients and physicians , enrollment in this trial was increased to 42 from the originally planned 25. in december 2015 , we presented preclinical data demonstrating the binding and clearance properties of neod001 and the related murine form of the antibody in various organs of patients with al amyloidosis . the data was featured in a poster session at the 57 th annual american society for hematology meeting . at the same meeting , we also presented a poster highlighting quality of life measures in patients with al amyloidosis . prx002 for parkinson 's disease and other related synucleinopathies in january 2016 , prothena added an additional dose level cohort to the ongoing phase 1 multiple ascending dose trial of prx002 in patients with parkinson 's disease . the decision to add an additional cohort of patients , dosed at 60 mg/kg , made jointly with roche , is intended to inform the design and dosing levels of future prx002 clinical studies , and was based in part on the observed safety and tolerability profile of prx002 at lower dose levels . this study will remain blinded to us until completion of the study , which we expect to occur following completion of the 60 mg/kg dose cohort follow-up period . this multiple ascending dose study is designed to assess prx002 for safety , tolerability , pharmacokinetics and immunogenicity . preclinical program in ttr amyloidosis in november 2015 , we presented preclinical results from a series of novel , conformation-specific protein immunotherapy antibodies that selectively bind to amyloidogenic ( diseased ) forms of the transthyretin ( attr ) protein at the first european congress on hereditary ttr amyloidosis . these data suggested that prothena 's antibodies have unique biological properties that may lead to the prevention of deposition , and enhancement of clearance of attr in patients with wild type and hereditary ttr-mediated amyloidosis . january 2016 offering in january 2016 , we completed an underwritten public offering of an aggregate of 2,587,500 of our ordinary shares at a public offering price of $ 53.00 per ordinary share . the company received aggregate net proceeds of approximately $ 128.6 million , after deducting the underwriting discount and estimated offering costs . critical accounting policies and estimates management 's discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements , which have been prepared in accordance with the accounting principles generally accepted in the u.s. ( `` gaap `` ) . the preparation of these consolidated financial statements requires us to make estimates and assumptions for the reported amounts of assets , liabilities , revenues , expenses and related disclosures . we believe the following policies to be critical to the judgments and estimates used in the preparation of our financial statements . revenue recognition revenue is recognized when earned and non-refundable , when payment is reasonably assured , and when there is no future obligation with respect to the revenue , in accordance with the terms prescribed in the applicable contract . 44 multiple element arrangements our revenues are generated primarily through our license , development and commercialization agreement . these types of agreements generally contain multiple elements , or deliverables , which may include ( i ) licenses to our technology , ( ii ) r & d activities to be performed on behalf of the collaborative partner , and ( iii ) in certain cases , services or obligations in connection with the manufacturing or supply of preclinical and clinical material . payments to us under these arrangements typically include one or more of the following : non-refundable , upfront license fees ; funding of research and or development efforts ; milestone payments ; and royalties on future product sales . revenue under license , development and commercialization agreements is recognized based on the performance requirements of the contract . determinations of whether persuasive evidence of an arrangement exists and whether delivery has occurred or services have been rendered are based on management 's judgments regarding the fixed nature of the fees charged for deliverables and the collectability of those fees . should changes in conditions cause management to determine that these criteria are not met for any new or modified transactions , revenue recognized could be adversely affected . we recognize revenue related to license , development and commercialization agreements in accordance with the provisions of fasb asc topic 605-25 , “ revenue recognition - multiple-element arrangements . ” we evaluate all deliverables within an arrangement to determine whether or not they provide value on a stand-alone basis . based on this evaluation , the deliverables are separated into units of accounting . story_separator_special_tag prx002 cost include payments to roche for our share of the development expenses incurred by roche related to prx002 programs and is net of reimbursements from roche for development and supply services recorded as an offset to r & d expense and , in 2014 , net of $ 1.7 million in offset to r & d expenses for a portion of the $ 15.0 million milestone received from 48 roche . for the years ended december 31 , 2015 and 2014 , $ 4.9 million and $ 2.4 million , respectively , were recorded as an offset to r & d expenses . ( 3 ) cumulative r & d costs to date for prx003 include the costs incurred from the date when the program has been separately tracked in preclinical development . expenditures in the early discovery stage are not tracked by program and accordingly have been excluded from this cumulative amount . ( 4 ) other r & d is comprised of preclinical development and discovery programs that have not progressed to first patient dosing in a phase 1 clinical trial , and for 2014 and 2013 also includes research costs we incurred in providing research services to elan . we expect our r & d expenses to continue to increase in 2016 primarily due to increased spending for the neod001 program in connection with the ongoing vital phase 3 clinical trial and the initiation of the pronto phase 2b clinical trial , and to a lesser extent increased spending for our attr preclinical program . general and administrative expenses our g & a expenses increased by $ 4.1 million , or 21 % , for the year ended december 31 , 2015 , compared to the prior year , primarily due to higher personnel costs , including share-based compensation expenses and legal fees associated with being a growing company . our g & a expenses increased by $ 4.0 million , or 27 % , for the year ended december 31 , 2014 compared to the prior year , primarily due to higher personnel costs , including share-based compensation expenses , and higher external consulting expenses . we expect our g & a expenses to continue to increase in 2016 in support of our anticipated r & d growth with increases in personnel , legal and other administrative expenses . other income ( expense ) replace_table_token_6_th interest income increased by $ 117,000 , or 148 % , for the year ended december 31 , 2015 , compared to the prior year , primarily due to higher balances in our cash and money market accounts . other income ( expense ) , net for the year ended december 31 , 2015 were primarily due to foreign exchange losses from transactions with vendors denominated in euros . interest income increased by $ 8,000 , or 11 % , for the year ended december 31 , 2014 compared to the prior year , primarily due to higher balances in our cash and money market accounts . other income ( expense ) , net for the year ended december 31 , 2014 was higher primarily due to foreign exchange income from transactions with vendors denominated in euros . provision for income taxes replace_table_token_7_th the tax provisions were $ 0.7 million , $ 0.8 million and $ 0.4 million for the years ended december 31 , 2015 , 2014 and 2013 . the tax provisions for all periods presented reflect u.s. federal taxes associated with recurring profits attributable to intercompany services that the company 's u.s. subsidiary performs for the company . no tax benefit has been recorded related to tax losses recognized in ireland and any deferred tax assets for those losses are offset by a valuation allowance . 49 liquidity and capital resources overview replace_table_token_8_th working capital was $ 355.2 million as of december 31 , 2015 , an increase of $ 68.1 million from working capital of $ 287.1 million as of december 31 , 2014 . this increase in working capital during the year ended december 31 , 2015 was principally attributable to a higher net cash and cash equivalents balance resulting from the net proceeds of $ 131.5 million from our public offering in the second quarter and to a lesser extent , from proceeds from issuance of ordinary shares upon exercise of stock options and from receivables collected from roche , partially offset by use of cash for operating expenses during the same period . as of december 31 , 2015 , we had $ 370.6 million in cash and cash equivalents . although we believe , based on our current business plans , that our existing cash and cash equivalents will be sufficient to meet our obligations for at least the next twelve months , we anticipate that we will require additional capital in the future in order to continue the research and development of our drug candidates . as of december 31 , 2015 , $ 34.0 million of our outstanding cash and cash equivalents related to u.s. operations that management asserts was permanently reinvested . we do not intend to repatriate these funds . however , if these funds were repatriated back to ireland we would incur a withholding tax from the dividend distribution . we have based this estimate on assumptions that may prove to be wrong , and we could use our available capital resources sooner than we currently expect . because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates , we are unable to estimate the amounts of increased capital outlays and operating expenses associated with completing the development of our product candidates . our future capital requirements will depend on numerous factors , including , without limitation , the timing of initiation , progress , results and costs of our clinical trials ; the results of our research and preclinical studies ; the costs of clinical manufacturing and of establishing

net cash used in operating activities was $ 62.5 million for the year ended december 31 , 2015 , primarily due to use of $ 81.5 million for operating expenses ( adjusted to exclude non-cash charges ) , which was partially offset by an increase in accrued liabilities . net cash used in operating activities was $ 0.7 million for the year ended december 31 , 2014 , primarily due to receipt of the upfront payment of $ 30.0 million , the clinical milestone payment of $ 15.0 million and reimbursement for research and development costs of $ 7.0 million from roche , recognized as revenue , offset by $ 57.5 million in expenses ( adjusted to exclude non-cash charges ) and increases in accrued liabilities . net cash used in operating activities was $ 32.1 million for the year ended december 31 , 2013 consisted primarily of net losses ( adjusted to exclude non-cash charges ) and changes in working capital accounts . cash used in investing activities net cash used in investing activities was $ 1.4 million , $ 0.5 million and $ 0.5 million for the years ended december 31 , 2015 , 2014 and 2013 , respectively , consisting of purchases of property and equipment .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```net cash used in operating activities was $ 62.5 million for the year ended december 31 , 2015 , primarily due to use of $ 81.5 million for operating expenses ( adjusted to exclude non-cash charges ) , which was partially offset by an increase in accrued liabilities . net cash used in operating activities was $ 0.7 million for the year ended december 31 , 2014 , primarily due to receipt of the upfront payment of $ 30.0 million , the clinical milestone payment of $ 15.0 million and reimbursement for research and development costs of $ 7.0 million from roche , recognized as revenue , offset by $ 57.5 million in expenses ( adjusted to exclude non-cash charges ) and increases in accrued liabilities . net cash used in operating activities was $ 32.1 million for the year ended december 31 , 2013 consisted primarily of net losses ( adjusted to exclude non-cash charges ) and changes in working capital accounts . cash used in investing activities net cash used in investing activities was $ 1.4 million , $ 0.5 million and $ 0.5 million for the years ended december 31 , 2015 , 2014 and 2013 , respectively , consisting of purchases of property and equipment .
```    
 Suspicious Activity Report : 43 recent developments neod001 for al amyloidosis in october 2015 , we announced plans to initiate pronto , a phase 2b registration-directed global , multi-center , randomized , double-blind , placebo-controlled clinical trial for neod001 in previously treated patients with al amyloidosis and with persistent cardiac dysfunction . the pronto trial is designed to enroll approximately 100 patients with a primary diagnosis of al amyloidosis and persistent cardiac dysfunction despite previous treatment with off-label , plasma cell directed therapy . patients will be randomized on a 1:1 basis to receive 24 mg/kg of neod001 or placebo via intravenous infusion every 28 days . the primary endpoint is cardiac best response as assessed by nt-probnp measured over 12 months . secondary endpoints include evaluations of short form 36 , six-minute walk test , and renal response as assessed by proteinuria . prothena designed the study with 80 % power to detect an absolute difference of 26.5 % in nt-probnp best response rate between the treatment and placebo groups with a two-sided alpha of 0.05. in october , we also announced the completion of enrollment for the expansion cohort of the phase 1/2 study of neod001 to treat patients with al amyloidosis and persistent organ dysfunction . based on strong interest from patients and physicians , enrollment in this trial was increased to 42 from the originally planned 25. in december 2015 , we presented preclinical data demonstrating the binding and clearance properties of neod001 and the related murine form of the antibody in various organs of patients with al amyloidosis . the data was featured in a poster session at the 57 th annual american society for hematology meeting . at the same meeting , we also presented a poster highlighting quality of life measures in patients with al amyloidosis . prx002 for parkinson 's disease and other related synucleinopathies in january 2016 , prothena added an additional dose level cohort to the ongoing phase 1 multiple ascending dose trial of prx002 in patients with parkinson 's disease . the decision to add an additional cohort of patients , dosed at 60 mg/kg , made jointly with roche , is intended to inform the design and dosing levels of future prx002 clinical studies , and was based in part on the observed safety and tolerability profile of prx002 at lower dose levels . this study will remain blinded to us until completion of the study , which we expect to occur following completion of the 60 mg/kg dose cohort follow-up period . this multiple ascending dose study is designed to assess prx002 for safety , tolerability , pharmacokinetics and immunogenicity . preclinical program in ttr amyloidosis in november 2015 , we presented preclinical results from a series of novel , conformation-specific protein immunotherapy antibodies that selectively bind to amyloidogenic ( diseased ) forms of the transthyretin ( attr ) protein at the first european congress on hereditary ttr amyloidosis . these data suggested that prothena 's antibodies have unique biological properties that may lead to the prevention of deposition , and enhancement of clearance of attr in patients with wild type and hereditary ttr-mediated amyloidosis . january 2016 offering in january 2016 , we completed an underwritten public offering of an aggregate of 2,587,500 of our ordinary shares at a public offering price of $ 53.00 per ordinary share . the company received aggregate net proceeds of approximately $ 128.6 million , after deducting the underwriting discount and estimated offering costs . critical accounting policies and estimates management 's discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements , which have been prepared in accordance with the accounting principles generally accepted in the u.s. ( `` gaap `` ) . the preparation of these consolidated financial statements requires us to make estimates and assumptions for the reported amounts of assets , liabilities , revenues , expenses and related disclosures . we believe the following policies to be critical to the judgments and estimates used in the preparation of our financial statements . revenue recognition revenue is recognized when earned and non-refundable , when payment is reasonably assured , and when there is no future obligation with respect to the revenue , in accordance with the terms prescribed in the applicable contract . 44 multiple element arrangements our revenues are generated primarily through our license , development and commercialization agreement . these types of agreements generally contain multiple elements , or deliverables , which may include ( i ) licenses to our technology , ( ii ) r & d activities to be performed on behalf of the collaborative partner , and ( iii ) in certain cases , services or obligations in connection with the manufacturing or supply of preclinical and clinical material . payments to us under these arrangements typically include one or more of the following : non-refundable , upfront license fees ; funding of research and or development efforts ; milestone payments ; and royalties on future product sales . revenue under license , development and commercialization agreements is recognized based on the performance requirements of the contract . determinations of whether persuasive evidence of an arrangement exists and whether delivery has occurred or services have been rendered are based on management 's judgments regarding the fixed nature of the fees charged for deliverables and the collectability of those fees . should changes in conditions cause management to determine that these criteria are not met for any new or modified transactions , revenue recognized could be adversely affected . we recognize revenue related to license , development and commercialization agreements in accordance with the provisions of fasb asc topic 605-25 , “ revenue recognition - multiple-element arrangements . ” we evaluate all deliverables within an arrangement to determine whether or not they provide value on a stand-alone basis . based on this evaluation , the deliverables are separated into units of accounting . story_separator_special_tag prx002 cost include payments to roche for our share of the development expenses incurred by roche related to prx002 programs and is net of reimbursements from roche for development and supply services recorded as an offset to r & d expense and , in 2014 , net of $ 1.7 million in offset to r & d expenses for a portion of the $ 15.0 million milestone received from 48 roche . for the years ended december 31 , 2015 and 2014 , $ 4.9 million and $ 2.4 million , respectively , were recorded as an offset to r & d expenses . ( 3 ) cumulative r & d costs to date for prx003 include the costs incurred from the date when the program has been separately tracked in preclinical development . expenditures in the early discovery stage are not tracked by program and accordingly have been excluded from this cumulative amount . ( 4 ) other r & d is comprised of preclinical development and discovery programs that have not progressed to first patient dosing in a phase 1 clinical trial , and for 2014 and 2013 also includes research costs we incurred in providing research services to elan . we expect our r & d expenses to continue to increase in 2016 primarily due to increased spending for the neod001 program in connection with the ongoing vital phase 3 clinical trial and the initiation of the pronto phase 2b clinical trial , and to a lesser extent increased spending for our attr preclinical program . general and administrative expenses our g & a expenses increased by $ 4.1 million , or 21 % , for the year ended december 31 , 2015 , compared to the prior year , primarily due to higher personnel costs , including share-based compensation expenses and legal fees associated with being a growing company . our g & a expenses increased by $ 4.0 million , or 27 % , for the year ended december 31 , 2014 compared to the prior year , primarily due to higher personnel costs , including share-based compensation expenses , and higher external consulting expenses . we expect our g & a expenses to continue to increase in 2016 in support of our anticipated r & d growth with increases in personnel , legal and other administrative expenses . other income ( expense ) replace_table_token_6_th interest income increased by $ 117,000 , or 148 % , for the year ended december 31 , 2015 , compared to the prior year , primarily due to higher balances in our cash and money market accounts . other income ( expense ) , net for the year ended december 31 , 2015 were primarily due to foreign exchange losses from transactions with vendors denominated in euros . interest income increased by $ 8,000 , or 11 % , for the year ended december 31 , 2014 compared to the prior year , primarily due to higher balances in our cash and money market accounts . other income ( expense ) , net for the year ended december 31 , 2014 was higher primarily due to foreign exchange income from transactions with vendors denominated in euros . provision for income taxes replace_table_token_7_th the tax provisions were $ 0.7 million , $ 0.8 million and $ 0.4 million for the years ended december 31 , 2015 , 2014 and 2013 . the tax provisions for all periods presented reflect u.s. federal taxes associated with recurring profits attributable to intercompany services that the company 's u.s. subsidiary performs for the company . no tax benefit has been recorded related to tax losses recognized in ireland and any deferred tax assets for those losses are offset by a valuation allowance . 49 liquidity and capital resources overview replace_table_token_8_th working capital was $ 355.2 million as of december 31 , 2015 , an increase of $ 68.1 million from working capital of $ 287.1 million as of december 31 , 2014 . this increase in working capital during the year ended december 31 , 2015 was principally attributable to a higher net cash and cash equivalents balance resulting from the net proceeds of $ 131.5 million from our public offering in the second quarter and to a lesser extent , from proceeds from issuance of ordinary shares upon exercise of stock options and from receivables collected from roche , partially offset by use of cash for operating expenses during the same period . as of december 31 , 2015 , we had $ 370.6 million in cash and cash equivalents . although we believe , based on our current business plans , that our existing cash and cash equivalents will be sufficient to meet our obligations for at least the next twelve months , we anticipate that we will require additional capital in the future in order to continue the research and development of our drug candidates . as of december 31 , 2015 , $ 34.0 million of our outstanding cash and cash equivalents related to u.s. operations that management asserts was permanently reinvested . we do not intend to repatriate these funds . however , if these funds were repatriated back to ireland we would incur a withholding tax from the dividend distribution . we have based this estimate on assumptions that may prove to be wrong , and we could use our available capital resources sooner than we currently expect . because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates , we are unable to estimate the amounts of increased capital outlays and operating expenses associated with completing the development of our product candidates . our future capital requirements will depend on numerous factors , including , without limitation , the timing of initiation , progress , results and costs of our clinical trials ; the results of our research and preclinical studies ; the costs of clinical manufacturing and of establishing

